FI112080B - 2-(2-amino-1,6-dihydro-6-oksopurin-9-yyli)metoksi-3-hydroksi-1-propanyyli-L-valinaatti - Google Patents

2-(2-amino-1,6-dihydro-6-oksopurin-9-yyli)metoksi-3-hydroksi-1-propanyyli-L-valinaatti Download PDF

Info

Publication number
FI112080B
FI112080B FI953592A FI953592A FI112080B FI 112080 B FI112080 B FI 112080B FI 953592 A FI953592 A FI 953592A FI 953592 A FI953592 A FI 953592A FI 112080 B FI112080 B FI 112080B
Authority
FI
Finland
Prior art keywords
amino
methoxy
dihydro
compound
oxopurin
Prior art date
Application number
FI953592A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI953592A0 (fi
FI953592A (fi
Inventor
John J Nestor
Scott W Womble
Hans Maag
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23079211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI112080(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of FI953592A0 publication Critical patent/FI953592A0/fi
Publication of FI953592A publication Critical patent/FI953592A/fi
Application granted granted Critical
Publication of FI112080B publication Critical patent/FI112080B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
FI953592A 1994-07-28 1995-07-27 2-(2-amino-1,6-dihydro-6-oksopurin-9-yyli)metoksi-3-hydroksi-1-propanyyli-L-valinaatti FI112080B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28189394A 1994-07-28 1994-07-28
US28189394 1994-07-28

Publications (3)

Publication Number Publication Date
FI953592A0 FI953592A0 (fi) 1995-07-27
FI953592A FI953592A (fi) 1996-01-29
FI112080B true FI112080B (fi) 2003-10-31

Family

ID=23079211

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953592A FI112080B (fi) 1994-07-28 1995-07-27 2-(2-amino-1,6-dihydro-6-oksopurin-9-yyli)metoksi-3-hydroksi-1-propanyyli-L-valinaatti

Country Status (33)

Country Link
EP (1) EP0694547B1 (ar)
JP (1) JP3090305B2 (ar)
KR (1) KR100358626B1 (ar)
CN (1) CN1045089C (ar)
AT (1) ATE179173T1 (ar)
AU (1) AU697107B2 (ar)
BR (1) BR9503468A (ar)
CA (1) CA2154721C (ar)
CO (1) CO4410181A1 (ar)
CY (2) CY2180B1 (ar)
CZ (1) CZ290511B6 (ar)
DE (3) DE69509173T2 (ar)
DK (1) DK0694547T3 (ar)
ES (1) ES2083348T3 (ar)
FI (1) FI112080B (ar)
GR (2) GR960300021T1 (ar)
HK (1) HK1012339A1 (ar)
HU (1) HU216867B (ar)
IL (1) IL114735A (ar)
LU (1) LU91136I2 (ar)
MA (1) MA23631A1 (ar)
MY (1) MY114393A (ar)
NL (1) NL300071I2 (ar)
NO (2) NO312899B1 (ar)
NZ (1) NZ272652A (ar)
PE (1) PE32296A1 (ar)
PL (1) PL180609B1 (ar)
RU (1) RU2133749C1 (ar)
SA (1) SA95160158B1 (ar)
TR (1) TR199500895A2 (ar)
TW (1) TW434242B (ar)
UY (1) UY24006A1 (ar)
ZA (1) ZA956228B (ar)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
AU1592897A (en) * 1996-01-26 1997-08-20 F. Hoffmann-La Roche Ag Process for preparing purine derivatives
AU1543797A (en) * 1996-01-26 1997-08-20 F. Hoffmann-La Roche Ag Process for preparing purine derivatives
US5840890A (en) * 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5700936A (en) * 1996-01-26 1997-12-23 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol valinate
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5869493A (en) * 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
US6703394B2 (en) 1996-02-16 2004-03-09 Medivir Ab Acyclic nucleoside derivatives
US6184376B1 (en) 1997-02-10 2001-02-06 Mediver Ab Synthesis of acyclic nucleoside derivatives
DE69809205T2 (de) * 1997-02-10 2003-05-28 Medivir Ab, Huddinge Verfahren zur herstellung von azyklischen nukleosiden
KR100529272B1 (ko) * 1997-08-15 2005-11-17 메디비르 아베 레트로바이러스 역전사효소 및 ｂ형 간염바이러스(ｈｂｖ)의 ｄｎａ 중합효소의 억제제를 포함한항바이러스제와 같은 뉴클레오시드 유사체
WO1999032490A1 (en) * 1997-12-19 1999-07-01 Bristol-Myers Squibb Company Prodrugs of lobucavir and methods of use
WO1999051613A1 (en) * 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
KR20030015655A (ko) * 2001-08-17 2003-02-25 한미약품공업 주식회사 항암제의 경구흡수율을 증가시키는 인단계 화합물의결정성 산부가염, 이의 제조방법 및 이를 함유하는 약학적조성물
DE60328675D1 (de) * 2002-04-23 2009-09-17 Aventis Pharma Inc 3-(substitutierte amino)-1h-indole-2-carbonsäureester und 3-(substitutierte amino)-benzoäbüthiophen-2-carbonsäureester verbindungen als inhibitoren der interleukin-4 genexpression
ES2534713T3 (es) 2002-10-16 2015-04-27 Takeda Pharmaceutical Company Limited Preparaciones sólidas estables
EA015145B1 (ru) 2003-01-14 2011-06-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
CA2537132A1 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Amorphous valganciclovir hydrochloride
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
PL1773878T3 (pl) * 2004-07-19 2015-07-31 Biocon Ltd Koniugaty insulina-oligomer, ich formulacje i zastosowania
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
ZA200702234B (en) * 2006-03-21 2008-07-30 Cipla Ltd Preparation of ester of purine derivatives
RU2010119041A (ru) 2007-10-12 2011-11-20 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи
WO2012163373A1 (en) 2011-05-31 2012-12-06 Pharmathen S.A. Process for the preparation of 2-amino-9-((2-phenyl-1,3-dioxan-5-yloxy)methyl)-1h-purin-6(9h)-one compound useful in the preparation of valganciclovir
KR102312533B1 (ko) 2021-02-24 2021-10-15 주식회사 이웅 자동 스패너

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8202626A (nl) * 1982-06-29 1984-01-16 Stichting Rega V Z W Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
IE842642L (en) * 1983-10-31 1985-04-30 Harvard College Purine Derivatives
NO172183C (no) * 1984-12-12 1993-06-16 Syntex Inc Fremgangsmaate for fremstilling av derivater av 9-(1,3-dikydroksy-2-propoksymetyl)-guanin
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
US5043339A (en) * 1988-12-19 1991-08-27 Burroughs Wellcome Co. Antiviral compounds

Also Published As

Publication number Publication date
HU216867B (hu) 1999-09-28
CO4410181A1 (es) 1997-01-09
DE694547T1 (de) 1996-10-24
DE69509173D1 (de) 1999-05-27
AU2719595A (en) 1996-02-08
ZA956228B (en) 1996-02-22
TW434242B (en) 2001-05-16
DE10299032I1 (de) 2003-01-23
NZ272652A (en) 1996-12-20
TR199500895A2 (tr) 1996-06-21
CZ290511B6 (cs) 2002-08-14
NO312899B1 (no) 2002-07-15
IL114735A (en) 1998-06-15
ATE179173T1 (de) 1999-05-15
KR100358626B1 (ko) 2003-01-14
JPH0841061A (ja) 1996-02-13
CY2004003I1 (el) 2009-11-04
MY114393A (en) 2002-10-31
HK1012339A1 (en) 1999-07-30
UY24006A1 (es) 2001-07-31
RU95113148A (ru) 1997-06-27
PL309812A1 (en) 1996-02-05
GR3030678T3 (en) 1999-11-30
FI953592A0 (fi) 1995-07-27
CZ193995A3 (en) 1996-02-14
IL114735A0 (en) 1995-11-27
PL180609B1 (pl) 2001-03-30
NO952977L (no) 1996-01-29
PE32296A1 (es) 1996-08-07
MA23631A1 (fr) 1996-04-01
CA2154721A1 (en) 1996-01-29
CY2180B1 (en) 2002-08-23
FI953592A (fi) 1996-01-29
NO2003001I2 (no) 2007-06-11
ES2083348T1 (es) 1996-04-16
CN1045089C (zh) 1999-09-15
KR960004345A (ko) 1996-02-23
DE69509173T2 (de) 1999-10-21
CN1122804A (zh) 1996-05-22
NL300071I2 (nl) 2002-03-01
ES2083348T3 (es) 1999-08-01
NO952977D0 (no) 1995-07-27
RU2133749C1 (ru) 1999-07-27
HU9502238D0 (en) 1995-09-28
NL300071I1 (nl) 2002-02-01
EP0694547B1 (en) 1999-04-21
DE10299032I2 (de) 2006-06-14
LU91136I2 (fr) 2005-07-06
JP3090305B2 (ja) 2000-09-18
HUT73246A (en) 1996-07-29
SA95160158B1 (ar) 2006-05-20
DK0694547T3 (da) 2000-01-03
BR9503468A (pt) 1996-02-27
CY2004003I2 (el) 2009-11-04
GR960300021T1 (en) 1996-04-30
EP0694547A3 (en) 1996-06-05
AU697107B2 (en) 1998-09-24
EP0694547A2 (en) 1996-01-31
CA2154721C (en) 2001-01-02

Similar Documents

Publication Publication Date Title
FI112080B (fi) 2-(2-amino-1,6-dihydro-6-oksopurin-9-yyli)metoksi-3-hydroksi-1-propanyyli-L-valinaatti
US6083953A (en) 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative
JP7367908B2 (ja) 標的タンパク質分解化合物、その抗腫瘍応用、その中間体および中間体の応用
FI89713B (fi) Foerfarande foer framstaellning av terapeutiskt aktivt 2-(2-amino-1,6-dihydro-6-oxo-9h(purin-9-yl)metoxi)etyl-l-valinat eller l-isoleucinat eller deras salt
US9315523B2 (en) Cyclic dinucleosides
US5543414A (en) Achiral amino acid acyl esters of ganciclovir and its derivatives
EP3919488A1 (en) Immunomodulator
EP1019403A1 (en) Process for preparing purine derivatives
EP2865669B1 (en) Novel rebamipide prodrug, method for producing same, and usage thereof
KR19990076616A (ko) 2,7-치환된 옥타하이드로-피롤로[1,2-에이]피라진 유도체
JP2001503767A (ja) ヌクレオシド
ES2180923T5 (es) Proceso para la preparacion de derivados de purina.
ES2641190T3 (es) Procedimiento de síntesis de IB-MECA
EP1891071B1 (en) Cyclopropanecarboxylate esters of acyclovir
TW202339766A (zh) 非環狀硫醇前藥
KR100290533B1 (ko) 항바이러스 활성을 가지는 2-아미노퓨린

Legal Events

Date Code Title Description
SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20040001

SPCE Application for extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: L20040001

MA Patent expired
SPCP Extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: 241

Extension date: 20170320